drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody
drug_description
Intravenous IgG1 monoclonal antibody targeting CD38 on malignant plasma cells; induces ADCC, CDC, ADCP, and direct apoptosis; inhibits CD38 ectoenzyme activity and depletes CD38+ immunosuppressive cells to enhance anti-myeloma immunity.
nci_thesaurus_concept_id
C90578
nci_thesaurus_preferred_term
Isatuximab
nci_thesaurus_definition
A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis eventually leading to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.
drug_mesh_term
Isatuximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Isatuximab is an IgG1 monoclonal antibody targeting CD38 on malignant plasma cells. It induces antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP), and can trigger direct apoptosis. It also inhibits CD38 ectoenzyme activity and depletes CD38+ immunosuppressive cells, enhancing anti-myeloma immune responses.
drug_name
Isatuximab
nct_id_drug_ref
NCT05776979